ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO061

NSAID Use and NSAID-Associated AKI Before and After Implementation of Pennsylvania’s Prescription Drug Monitoring Program

Session Information

Category: Acute Kidney Injury

  • 101 AKI: Epidemiology, Risk Factors, and Prevention


  • Ray, Evan C., University of Pittsburgh, Pittsburgh, Pennsylvania, United States
  • Bilderback, Andrew, UPMC, Pittsburgh, Pennsylvania, United States
  • Schwenk, Amanda, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
  • Dealmeida, Dilhari, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
  • Kellum, John A., University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Few studies describe the influence of prescription drug monitoring programs (PDMPs) on NSAID use or NSAID-associated adverse effects. We asked whether implementation of Pennsylvania’s PDMP, designed to reduce narcotic use, was associated with changes in inpatient NSAID administration or NSAID-related Acute Kidney Injury (AKI) in western Pennsylvania (UPMC) hospitals.


We examined retrospective data from 16 UPMC hospitals in three PA PDMP phases: pre-PDMP (Jan 1-Aug 25, 2016), voluntary PDMP participation (Aug 26-Dec 31, 2016), and mandatory PDMP participation (Jan 1-Dec 31, 2017). Patients with ICD-10 codes indicating ESRD or kidney transplant were excluded. Outcomes included percent of admissions with any NSAID use and with prolonged NSAID use (≥ 4 days) and frequency of NSAID-associated AKI. AKI was defined by presence of both a creatinine-based electronic flag and an ICD-10 code for atraumatic, non-obstructive AKI. Outcomes were compared during each phase using chi-square tests, and interrupted time-series analyses were used to examine the impact of each phase over time.


Inpatient visits in the pre-, voluntary, and mandatory PDMP phases totaled 95,550; 52,344; and 151,251, respectively. Across the three phases, hospitalizations with any NSAID use increased (77.1% pre- vs 78.3% voluntary vs 79.5% mandatory PDMP, p<0.001). Additionally, hospitalizations with prolonged NSAID use increased across the three phases (32.1% pre- vs 32.6% voluntary vs 33.9% mandatory PDMP, p=0.001). In interrupted time series analysis, receipt of any NSAIDs increased 1.4% with implementation of the voluntary phase (p <0.001), and AKI incidence increased 0.7% with implementation of the mandatory phase (p=0.06). Across all phases, patients with CKD were particularly susceptible to NSAID-associated AKI with prolonged NSAID use, as 42.0% of CKD patients receiving NSAIDs for ≥ 4 days experienced AKI, compared to 29.9% of CKD patients receiving < 4 days of NSAIDs (p = 0.001).


We find that implementation of the PA PDMP was associated with a significant increase in NSAID use and duration in inpatient UPMC facilities and a marginally significant and temporally correlated increase in AKI. Further analyses will examine whether AKI increased more dramatically in specific high-risk patient subsets.


  • NIDDK Support